Pediatric Diabetes

SAN DIEGO — In this video exclusive, Anastasia Albanese-O’Neill, PhD, APRN, RN, CDCES, discusses the need for type 1 diabetes screening and monitoring now that a therapy to delay the disease is available.

The use of continuous glucose monitoring and hybrid closed-loop insulin delivery systems increased among youths with type 1 diabetes from 2016-2017 to 2020-2021 and may have helped reduce HbA1c, according to a brief report.

The FDA has approved two forms of empagliflozin as an adjunct to diet and exercise to improve glycemic control in children with type 2 diabetes, according to a press release.

Boston Children’s Hospital and Cincinnati Children’s Hospital Medical Center have both been named co-No. 1 hospitals for pediatric diabetes and endocrinology, according to the U.S. News & World Report.

CHICAGO — Children with type 1 diabetes using closed-loop insulin delivery systems spend more time in range than those receiving insulin injections or using a sensor-augmented pump or continuous glucose monitor, according to study data.

Fast-acting insulin aspart delivered through a hybrid closed-loop insulin delivery system provided similar glycemic outcomes as standard insulin aspart for young children with type 1 diabetes, according to study data.

Older children with newly diagnosed type 1 diabetes who received intensive diabetes management with automated insulin delivery had no difference in pancreatic C-peptide levels compared with standard care, according to study data.

Once-daily oral verapamil may help preserve stimulated C-peptide secretion for children and adolescents with type 1 diabetes, according to a study published in JAMA.

Analyzing psychosocial health and patient-reported outcomes is necessary when treating people with diabetes, and practices should incorporate screening into routine care, according to a review article published in Current Diabetes Reports.

Advanced hybrid closed-loop therapy reduces HbA1c and improves time in range among adolescents and young adults with type 1 diabetes, with few serious adverse events, according to findings published in Diabetes Care.